This minisymposium topic describing the ways in which AI’s robustness, interpretability, and portability is being advanced in ophthalmology is novel in that it will be the first-of-its-kind at EMBC to bring AI and medical experts together to focus on AI in a particular branch of medicine, especially one which is having so much success.
Both the engineering and medical communities that make up EMBS will appreciate such a minisymposium to meet key players in this field, build further collaborations, and add their expertise to the conversation. Toward robustness, you’ll hear from LumineticsCore (formerly IDx-DR) creator Dr. Michael Abramoff, whose invention serves as an example of an FDA cleared AI system which is now part of the American Diabetes Association’s Standard Diabetes Care for diabetic retinopathy screening.